earnings per fully diluted share was $num-one in the fourth quarter, compared to $num-two per share in the same quarter prior year.
we expect revenue to be in the range of $num-one billion to $num-two billion for the full year of year-seven.
for the full year, earnings per fully diluted share were $num-one compared to $num-two per share in the prior year.
we are also reaffirming our previously issued three-year compound annual growth rate target for revenue only, which we expect to be in the range of num-one% to num-two% for year-six through year-eight.
total company revenue for the fourth quarter was $num-one billion, a num-two% increase compared to the same quarter prior year.
for the full year, total company revenue increased num-one% to $num-two billion, compared to $num-three billion in the prior year.
i also wanted to note that we recorded $num-one million in other operating income in the fourth quarter, and $num-two million for the full year year-six related to provider relief fund grant payments.
adjusted earnings per fully diluted share last year was $num-one, excluding non-operating gains and their related tax effects.
our revenues grew nicely in all four of our business segments, with aggregate revenue growth for the quarter close to num-one% and for the year, over num-two%.
revenue in our critical illness recovery hospitals segment in the fourth quarter increased num-one% to $num-two million compared to $num-three million in the same quarter prior year.
net income attributable to select medical holdings was $num-one million in the fourth quarter and fully diluted earnings per share were $num-two.
net revenue per patient day increased num-one% to $num-two per patient day in the fourth quarter, as case mix index was num-three in the fourth quarter compared to num-four in the same quarter last year.
in year-five, we recorded $num-one million in other operating income in the fourth quarter, and $num-two million for the full year year-five related to these payments.
the concentra segment does include $num-one million in the fourth quarter and $num-two million for the full year year-six of adjusted ebitda related to these funds.
we also recorded interest income of $num-one in the fourth quarter this year.
we expect our capital expenditure to be in the range of $num-one million to $num-two million for this year.